Objective: The relative preventative efficacy of amiodarone and lidocaine for ventricular fibrillation (VF) after release of an aortic cross-clamp (ACC) during open heart surgery has not been determined. This meta-analysis was designed to systematically evaluate the influence of amiodarone, lidocaine, or placebo on the incidence of VF after ACC. Methods: Prospective randomized controlled trials (RCTs) that compared the VF-preventative effects of amiodarone with lidocaine, or amiodarone or lidocaine with placebo were included. PubMed, EMBASE, and the Cochrane Library were searched for relevant RCTs. Fixed or randomized effect models were applied according to the heterogeneity of the data from the selected studies. Results: We included eight RCTs in the analysis. Pooled results suggested that the preventative effects of amiodarone and lidocaine were comparable (relative risk (RR)=1.12, 95% confidence interval (CI): 0.70 to 1.80, P=0.63), but both were superior to the placebo (amiodarone, RR=0.71, 95% CI: 0.51 to 1.00, P=0.05; lidocaine, RR=0.63, 95% CI: 0.46 to 0.88, P=0.006). The percentage of patients requiring electric defibrillation counter shocks (DCSs) did not differ significantly among patients administered amiodarone (RR=0.21, 95% CI: 0.04 to 1.19, P=0.08), lidocaine (RR=2.44, 95% CI: 0.13 to 44.02, P=0.55), or the placebo (RR=0.56, 95% CI: 0.25 to 1.25, P=0.16). Conclusions: Amiodarone and lidocaine are comparably effective in preventing VF after ACC, but the percentage of patients who subsequently require DCSs does not differ among those administered amiodarone, lidocaine, or placebo.
heart diseases (CHD) (Verrier and Mack, 2015; Papakonstantinou et al., 2017) , severe valvular heart diseases (Geissler et al., 2009) , and complicated congenital heart diseases (Mery and Kane, 2017) . With improvements in perioperative care and cardiopulmonary bypass (CPB) techniques, the indications for cardiac surgery have been expanded and many patients who were previously deemed to be contraindicated or intolerant to cardiac surgeries are now considered suitable for open heart surgery (Marathe and Talwar, 2015) . However, patients who undergo cardiac surgery are still at risk of fatal complications associated with both the surgical procedures and CPB, such as major bleeding, infection, and most importantly, lethal arrhythmias, such as ventricular fibrillation (VF) (Shake et al., 2013; Zhan et al., 2015) . Pathophysiologically, VF is associated with myocardial ischemia and reperfusion injury, and subsequent inflammatory responses, oxidative stress, and electrical instability (Yeh et al., 2013; Patil et al., 2015) . VF occurs most frequently after aortic cross-clamp (ACC) release during the coronary artery bypass graft (CABG) procedure, when myocardium reperfusion is initiated (Leeuwenburgh et al., 2008) . The incidence of VF after ACC release is reported to vary with the experience of the surgeon and the category of surgical procedures, ranging from 45% to 90% in patients undergoing CABG (Leeuwenburgh et al., 2008; Baravelli et al., 2010) . When VF occurs during cardiac surgery, the most effective treatment strategy is electric defibrillation counter shocks (DCSs). However, the success rate of DCSs for patients with VF during open heart cardiac surgery is not satisfactory. Moreover, even in patients for whom VF was successfully terminated after DCSs, the procedure is associated with potential secondary damage to the myocardium, possibly leading to cardiac dysfunction and recurrent lethal arrhythmia (Doherty et al., 1979; Yamaguchi et al., 2002) . Therefore, prophylactic measures capable of reducing the risk of VF after ACC release in patients undergoing cardiac surgery are urgently sought to improve the prognosis of these patients.
Perioperative administration of conventional antiarrhythmic medications has been suggested for effective prevention of VF after ACC release in patients undergoing cardiac surgery (Hippelainen et al., 1994; Schluter et al., 2001) . The capacity of two conventional antiarrhythmic medications, amiodarone and lidocaine, to prevent VF during cardiac surgery has been assessed clinically, but the results are contradictory. Two early studies concluded that a cardioplegic solution containing lidocaine can significantly reduce VF incidence by 22%-42% in patients undergoing cardiac surgery (Fiore et al., 1990; Baraka et al., 1993) . Moreover, another study indicated that administration of lidocaine with a perfusion pump before ACC release reduced VF incidence from 70% to 11% (Baraka et al., 2000) . As for amiodarone, subsequent studies demonstrated that this medication may achieve comparable (Samantaray et al., 2010) or even greater (Dorian et al., 2002) preventative effects against VF in patients who are at risk for development of VF and pulseless ventricular tachycardia during cardiac surgery. In contrast, several other studies reported that neither amiodarone nor lidocaine effectively prevented VF in cardiac surgeries. A randomized controlled trial (RCT) conducted by Ayoub et al. (2009) concluded that VF incidence did not differ significantly between patients who received amiodarone and those who received placebo. Furthermore, a subsequent three-armed RCT reported no significant difference in VF incidence after ACC release in patients undergoing cardiac surgery who were administered amiodarone, lidocaine, or placebo (Ghavidel et al., 2013) . Many factors have been proposed to explain these inconsistencies in clinical trial results, including their inadequate statistical power produced by small numbers of patients. Therefore, in this study, we performed a meta-analysis of head-to-head RCTs to compare the capacity of amiodarone, lidocaine, and placebo to prevent VF after ACC release in patients undergoing cardiac surgery.
Materials and methods

Literature search
Our study followed the recommendations of the PRISMA 2009 checklist (Moher et al., 2009) and the Cochrane Handbook for Systematic Reviews of Interventions 5.0.2. Electronic databases (PubMed, EMBASE, and Cochrane Central Register of Controlled Trials) were searched for relevant RCTs with the keywords amiodarone or lidocaine, paired with ventricular fibrillation or reperfusion. The language was restricted to English and the final search was performed on August 25th, 2017. Moreover, the reference lists from the identified articles were manually searched for additional relevant studies. Two investigators (YZ, QG) independently reviewed the literature and articles fulfilling the following criteria were selected: (1) designed as an RCT; (2) included adult patients undergoing cardiac surgery requiring ACC; (3) patients were assigned to either 2 or 3 of the following interventional groups: amiodarone, lidocaine, or placebo; (4) reported outcome data included VF incidence or percentage of patients requiring electric DCSs. Reviews, case reports, retrospective studies, observational studies, or studies with unavailable outcome data were excluded.
Data extraction and quality assessment
We extracted data regarding patient demographics (age, gender), type of surgery, duration of ACC, and duration of CPB. Where possible we used intentionto-treat (ITT) data, but where this was unavailable we extracted data from tables or graphs in each article or retrieved data directly from authors. The quality of all selected studies was evaluated based on the Cochrane Back Review Group 12-item scale (Furlan et al., 2015) . Two reviewers (YZ, QG) independently extracted data and evaluated the quality of the RCTs, and any disagreements were resolved by consulting a third investigator (MX).
Statistical analysis
Dichotomous variables were assessed according to relative risk (RR) and 95% confidence interval (CI). The Cochrane's Q test and I 2 test were used to measure the statistical heterogeneity. I 2 values of 25%, 50%, and 75% were considered to indicate low, moderate, and high statistical heterogeneity, respectively. Random effect models were used to pool the results as these can incorporate the inherited heterogeneity among the studies. Subgroup analyses and meta-regression were performed to evaluate potential sources of heterogeneity if sufficient numbers of interventional groups were included. Publication bias among the included studies was analyzed by a funnel plot and Egger's regression test. All analyses were conducted with RevMan software (Review Manager, Version 5.3, the Cochrane Collaboration, Oxford, UK) and STATA software 12.0 (StataCorp, College Station, Texas, USA).
Results
Literature review
The initial search retrieved 4465 relevant citations (PubMed 1493, EMBASE 2634, and the Cochrane's Library 338), and finally 8 RCTs were included in our meta-analysis. The literature searching procedure is described in Fig. 1 .
Quality assessment and characteristics of included studies
Overall, 8 RCTs were selected, which included a total of 839 patients: 249 treated with amiodarone, 288 treated with lidocaine, and 302 with placebo. All included studies were RCTs and, according to the item standard quality evaluation, five were classified as high-quality and the other three as moderate quality studies (Table 1) . Among these studies, four were three-arm trials (Ayoub et al., 2009; Mauermann et al., 2012; Ghavidel et al., 2013; Yilmaz et al., 2014) of amiodarone versus lidocaine versus placebo, three compared lidocaine with placebo (Kirlangitis et al., 1990; Baraka et al., 2000; Vaziri et al., 2010) , and one compared amiodarone with placebo (Samantaray et al., 2010) . In all studies, all patients were scheduled to undergo elective surgery and were age-, gender-, and operative condition-matched (Table 2) .
Effects of amiodarone and lidocaine on VF incidence after release of ACC
Four of the eight trials, including a total of 466 patients, directly compared the efficacy of amiodarone and lidocaine. The rate of VF after release of ACC did not differ significantly between patients treated with amiodarone and lidocaine (RR=1.12, 95% CI: 0.70 to 1.80, P=0.63; Fig. 2a Only if the sequencing method was explicitly introduced was a study given a ''Yes''; sequence generated by ''Dates of Admission'' or ''Patient's Number'' received a ''No''; b Drop-out rates <20% were given a ''Yes'', otherwise ''No''; c ITT: intention-to-treat; only if all randomized participants were analyzed in the group to which they were allocated was a study given a ''Yes''; d Studies with more than 7 items were scored as ''High''; those with more than 4, but no more than 7 items were scored as ''Moderate''; those with no more than 4 items were scored as ''Low'' Publication bias was difficult to estimate due to the small number of comparisons included.
Effects of amiodarone and lidocaine on rate of DCSs after release of ACC
Three of the eight trials including a total of 214 patients compared the percentage of patients requiring DCSs for VF. Our results showed that this rate did not differ significantly between amiodarone and placebo groups (RR=0.56, 95% CI: 0.25 to 1.25, P=0.16; Fig. 3a ) with moderate heterogeneity (I 2 =51%, P=0.13). Similarly, the percentage of patients requiring DCSs for VF did not differ significantly between patients receiving lidocaine and placebo (3 trials, 214 patients; RR=0.21, 95% CI: 0.04 to 1.19, P=0.08; Fig. 3b ; I 2 =71%, P=0.03) and those receiving amiodarone and lidocaine (2 trials, 180 patients; RR=2.44, 95% CI: 0.13 to 44.02, P=0.55; Fig. 3c ). However, significant heterogeneity was detected (I 2 =84%, P=0.01). Subsequent subgroup and metaregression analyses were not performed due to the small number of studies. Publication bias was difficult to estimate due to the small number of comparisons included.
Discussion
By integrating all available RCTs, the results of our meta-analysis indicate that amiodarone and lidocaine confer comparable preventative efficacy for VF incidence after ACC release in patients undergoing open heart surgery, and that the effects of each were significant compared with placebos. However, when the percentage of patients subsequently requiring DCSs for reperfusion VF was applied as the measure, no significant effects among amiodarone, lidocaine, and placebo were detected. Overall, the included The rate of VF after release of ACC did not differ significantly between patients undergoing open heart surgery who were treated with amiodarone or lidocaine (a); amiodarone (b) and lidocaine (c) were associated with a lower risk of VF than placebo studies represented a small sample size, and moderate to significant heterogeneity was detected among the included RCTs. Based on the results, our study indicated that perioperative administrations of amiodarone and lidocaine confer similar preventative efficacy for VF incidence after ACC release in patients undergoing open heart surgery. These results may highlight the potential use of conventional antiarrhythmic medications for the prevention of VF during cardiac surgery procedures. Further studies with larger numbers of participants are needed to confirm our results, and to determine the protocol and regimens for the perioperative administrations of amiodarone and lidocaine during open heart surgery.
The incidence of VF following ACC release during cardiac surgery is relatively high and is associated with poor prognosis in patients undergoing cardiac surgery. Previous studies indicated that medications administered to prevent arrhythmia may also effectively prevent VF during cardiac surgery (Wenger et al., 1984; Kirlangitis et al., 1990; Komori et al., 1999; Ayoub et al., 2009) . Amiodarone and lidocaine are the most commonly used drugs for the prevention of heart arrhythmia (Wyman et al., 2004; Nayeem Ul et al., 2013; Onk and Erkut, 2015) . However, studies directly comparing the effects of amiodarone and lidocaine on VF following ACC release during cardiac surgery have rarely been reported. Our meta-analysis revealed that the capacity of amiodarone and lidocaine to prevent reperfusion VF was similar, consistent with previous RCTs (Mauermann et al., 2012; Ghavidel et al., 2013) . However, some studies raised the possibility that lidocaine may more effectively prevent VF following ACC release in patients undergoing cardiac surgery (Ayoub et al., 2009) . Amiodarone acts to stabilize the membrane of cardiomyocytes and was widely used for the prevention and treatment of atrial and ventricular arrhythmia, including VF (Levine et al., 1996; Petrovic et al., 1998; Somberg et al., 2002) . Regarding The rate did not differ significantly between amiodarone and placebo groups (a); the percentage of patients requiring DCSs for VF did not differ significantly between patients receiving lidocaine and placebo (b) and those receiving amiodarone and lidocaine (c) the potential mechanisms by which amiodarone may prevent VF during cardiac surgery, some recently published experimental studies may provide some novel evidence. In a swine model of hemorrhageinduced VF, resuscitation combined with amiodarone and vasopressin after hemorrhagic circulatory arrest resulted in better 3-h survival, better preservation of hemodynamic parameters, and less myocardial injury than resuscitation with vasopressin only, indicating the efficacy of amiodarone for termination of VF (Zoerner and Semenas, 2014) . This observation is consistent with previous studies which showed that administration of amiodarone may be associated with a lower long-duration ventricular defibrillation threshold (Wu et al., 2011; Chevalier et al., 2012) , suggesting a beneficial effect of amiodarone on malignant arrhythmias. Similarly, lidocaine was also recommended as an antiarrhythmic drug for recurrent VF (American Heart Association, 1992; . However, few experimental studies have investigated the mechanism by which lidocaine may reduce VF incidence, and the effect of this drug on VF in animal models during cardiac surgery has rarely been reported. The mechanisms mediating lidocaine's effect on the risk of VF after ACC release in patients undergoing open heart surgery require further investigation.
In this study, we observed no significant differences in the effects of amiodarone, lidocaine, or placebo on the ratio of patients who subsequently required DCSs for the conversion of VF following cardiac surgery. This observation is inconsistent with the observed differences in VF incidence, perhaps as far fewer studies reported the DCS outcome, and the statistic power of the pooled analyses therefore was more limited.
Our conclusions are limited by the scope of this study, which should be considered when interpreting the results. Firstly, we included the results of only 8 RCTs including a total of 839 patients. The small number of RCTs included and the small sample size of each included study restricted further analyses of the other factors that may influence the outcomes, such as patient demographic factors, surgical categories, and patient comorbidities. Obviously, large-scale RCTs with adequate statistic power are required to confirm our results. Secondly, the quality of the included studies was moderate, which led to the moderate grade of our meta-analyses. Thirdly, the results of our meta-analysis are based on the pooled results of crude RRs, which may be biased by potential confounding factors that were not balanced between groups during randomization. However, as a metaanalysis of RCTs, the chances of potential bias caused by residual confounding factors are low when compared with meta-analyses of observational studies. In addition, the optimal protocols and dosages for the administration of amiodarone and lidocaine during the perioperative periods remain to be determined in future studies. Lastly, publication bias among the included studies was difficult to estimate since only a small number of studies were available. Publication bias may exist since we extracted only English language articles.
Conclusions
In conclusion, the current evidence from headto-head RCTs suggests that amiodarone and lidocaine have comparable preventative efficacy for VF after ACC, but the ratio of patients who subsequently require DCSs does not differ between amiodarone, lidocaine, and placebo groups. Further studies with a larger number of participants will be required to confirm our results.
